Celgene’s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped. Robert Mayer, the Stephen B. Kay Family Professor of Medicine at the Dana-Farber Cancer Institute, is quoted.
